Last reviewed · How we verify
EBP05
EBP05 is a recombinant human glucagon-like peptide-2 (GLP-2) analog.
EBP05 is a recombinant human glucagon-like peptide-2 (GLP-2) analog. Used for Short bowel syndrome.
At a glance
| Generic name | EBP05 |
|---|---|
| Also known as | hPTH(1-34), Teriparatide |
| Sponsor | Entera Bio Ltd. |
| Drug class | GLP-2 analog |
| Target | GLP-2 receptor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 2 |
Mechanism of action
It works by mimicking the action of GLP-2, a naturally occurring peptide hormone that promotes intestinal growth and adaptation. This can lead to improved nutrient absorption and potentially enhanced recovery from gastrointestinal damage.
Approved indications
- Short bowel syndrome
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo (PHASE1)
- A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass (PHASE2)
- Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |